149 related articles for article (PubMed ID: 18473194)
1. Fatal anaphylactic reaction to iron sucrose in pregnancy.
Mishra A; Dave N; Viradiya K
Indian J Pharmacol; 2013; 45(1):93-4. PubMed ID: 23543624
[TBL] [Abstract][Full Text] [Related]
2. Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure.
Zdravkovic SC; Nagorni SP; Cojbasic I; Mitic V; Cvetkovic P; Nagorni I; Govedarovic N; Davinic I; Stanojevic D
J Int Med Res; 2019 Jul; 47(7):3179-3189. PubMed ID: 31189356
[TBL] [Abstract][Full Text] [Related]
3. Effects of iron supplementation on erythropoietic response in patients with cancer-associated anemia treated by means of erythropoietic stimulating agents.
Karlsson T
ISRN Hematol; 2011; 2011():108397. PubMed ID: 22111015
[TBL] [Abstract][Full Text] [Related]
4. Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy.
Busti F; Marchi G; Ugolini S; Castagna A; Girelli D
Pharmaceuticals (Basel); 2018 Sep; 11(4):. PubMed ID: 30274354
[TBL] [Abstract][Full Text] [Related]
5. Iron metabolism and iron supplementation in cancer patients.
Ludwig H; Evstatiev R; Kornek G; Aapro M; Bauernhofer T; Buxhofer-Ausch V; Fridrik M; Geissler D; Geissler K; Gisslinger H; Koller E; Kopetzky G; Lang A; Rumpold H; Steurer M; Kamali H; Link H
Wien Klin Wochenschr; 2015 Dec; 127(23-24):907-19. PubMed ID: 26373748
[TBL] [Abstract][Full Text] [Related]
6. Oral iron supplementation: new formulations, old questions.
Pantopoulos K
Haematologica; 2024 Apr; ():. PubMed ID: 38618666
[TBL] [Abstract][Full Text] [Related]
7. Managing anemia in lymphoma and multiple myeloma.
Birgegård G
Ther Clin Risk Manag; 2008 Apr; 4(2):527-39. PubMed ID: 18728848
[TBL] [Abstract][Full Text] [Related]
8. [Intravenous iron therapy with ferrum injectabile Vitis].
PRIBILLA W
Medizinische; 1952 Jun; 2():53-6. PubMed ID: 14940483
[No Abstract] [Full Text] [Related]
9. The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy.
Rodgers GM; Gilreath JA
Acta Haematol; 2019; 142(1):13-20. PubMed ID: 30970366
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of IV ferumoxytol for iron deficiency anemia in patients with cancer.
Vadhan-Raj S; Dahl NV; Bernard K; Li Z; Strauss WE
J Blood Med; 2017; 8():199-209. PubMed ID: 29263710
[TBL] [Abstract][Full Text] [Related]
11. Is there any role of intravenous iron for the treatment of anemia in cancer?
Gemici C; Yetmen O; Yaprak G; Ozden S; Tepetam H; Ozyurt H; Mayadagli A
BMC Cancer; 2016 Aug; 16(1):661. PubMed ID: 27542823
[TBL] [Abstract][Full Text] [Related]
12. Mn bioavailability by polarized Caco-2 cells: comparison between Mn gluconate and Mn oxyprolinate.
Foglieni C; Cavarelli M; Piscopiello M; Fulgenzi A; Ferrero ME
Nutr J; 2011 Jul; 10():77. PubMed ID: 21781350
[TBL] [Abstract][Full Text] [Related]
13. High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients.
Caravita T; Siniscalchi A; Montanaro M; Niscola P; Stasi R; Amadori S; de Fabritiis P
Int J Hematol; 2009 Sep; 90(2):270-272. PubMed ID: 19609645
[No Abstract] [Full Text] [Related]
14. The role of iron supplementation during epoietin treatment for cancer-related anemia.
Hedenus M; Birgegård G
Med Oncol; 2009; 26(1):105-15. PubMed ID: 18473194
[TBL] [Abstract][Full Text] [Related]
15. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
16. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
17. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
